Drugs / Recombinant S protein SARS vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01376765 | — | severe acute respiratory syndrome | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant S protein SARS vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01376765 ↗ |
| Modality | Vaccine | “Recombinant S protein severe acute respiratory syndrome (SARS) vaccine” NCT01376765 ↗ |
| Route | Intramuscular | “2 intramuscular doses, 28 days apart” NCT01376765 ↗ |